The Duchenne Muscular Dystrophy (DMD) Therapeutics Market is being driven by High unmet need for duchenne muscular dystrophy therapeutics
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market is expected to grow at a CAGR of 28.21% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 4373.3 million. In the global Duchenne Muscular Dystrophy (DMD) therapeutics market, numerous prominent pharmaceutical companies are actively engaged in the research and development of innovative therapeutics to address the significant unmet medical need for effective treatments. The progressive nature of DMD and the limited availability of therapeutic options have created a substantial market opportunity. Vendors are exploring various approaches, including antisense oligonucleotide-based therapy, gene therapy, cell therapy, biologics, and small molecule-based drugs. Notably, in February 2021, Sarepta Therapeutics secured FDA approval for AMONDYS 45 (casimersen) injection, expanding the treatment landscape for DMD patients amenable to exon 45 skipping. This approval underscores the growing pipeline for DMD therapeutics and the industry's commitment to delivering novel solutions for patients.
Get more information on Duchenne Muscular Dystrophy (DMD) Therapeutics Market by requesting a sample report
Which Factors Are Causing a Surge in Market Growth?
The market is segmented based on Type (Biologics, Small molecules) Distribution Channel (Offline, Online) Geography (North America, Europe, Asia, Rest of World (ROW)).
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Key Features in Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report
Find out which segment is leading the market by accessing the free PDF report
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market encompasses the development of potential treatments through clinical trials, with a focus on cost assessment, optimization, and effectiveness. Treatment cost data, implications, and projections are crucial in shaping strategies for burden reduction. Exon skipping therapy and other pharmaceutical interventions target muscle damage, regeneration, and degeneration. Porter's Five Forces analysis in the DMD healthcare sector influences drug development and cost factors, aiming for cost-effective medication and muscle function improvement. Biotechnology plays a significant role in muscle atrophy, muscle strength, and muscle repair, addressing muscle weakness and deterioration in patients.
The Duchenne Muscular Dystrophy (DMD) therapeutics market is a significant segment within the global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of approved pharmacological therapies. Key treatments include corticosteroids, which help slow disease progression and improve muscle function. The impact of these therapies on individuals and their families is substantial, making public sector investment in clinical trials crucial. The global pharmaceuticals market is projected to grow, driven by factors such as an aging population, with Europe and the US forecasted to have over 25% of their populations aged 60 and above by 2030 and 2050, respectively. This demographic shift will increase the demand for various healthcare solutions, including DMD therapies.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
